Categories Earnings, Health Care

Amarin’s Q3 results top estimates

Amarin Corporation plc (NASDAQ: AMRN) reported better-than-expected revenue and earnings for the third quarter of 2019, allowing the stock to gain 2% during premarket hours on Tuesday.

Total revenue of $112.4 million was up 103% compared to the prior-year period and above estimates of $110 million.  

GAAP net loss was $3.5 million, or $0.01 per share, compared to a loss of $24.5 million, or $0.08 per share, last year. Adjusted net income was $4.5 million, or $0.01 per share. Analysts had forecast adjusted loss of $0.05 per share.

Amarin quarterly product revenue and Vascepa prescription growth

Net product revenue increased 104% year-over-year to $112.3 million, driven mainly by an increase in total Vascepa prescriptions in the US. The increased prescription levels reflect both a higher number of Vascepa prescribers and an increase in the average prescriptions per prescriber.

Based on data provided by Symphony Health and IQVIA, the estimated number of normalized total Vascepa prescriptions for the quarter were approx. 865,000 and 787,000, respectively, reflecting increases of 89% over the year-ago period. The increase in prescriptions were mainly across the US.

Also read: Bausch Health Q3 2019 Earnings Report

Gross margin on net product revenue was 77% in the third quarter compared to 75% in the same period a year earlier.

R&D expense decreased 37% year-over-year to $8.9 million, mainly due to the decline in REDUCE-IT related costs.  

For full-year 2019, Amarin expects revenues to be $380 million to $420 million.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top